Lv5
1410 积分 2026-01-18 加入
MSR125 Methodology for Estimating Equal Value Life-Year for Standard Three-State Partitioned Survival Models
8天前
已关闭
Mitigating the regressivity of private mechanisms of financing healthcare: An Assessment of 29 countries
15天前
已关闭
Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study
23天前
已完结
Cost Effectiveness of the First‐in‐Class ARNI (Sacubitril/Valsartan) for the Treatment of Essential Hypertension in a Chinese Setting
1个月前
已完结
Cost-Utility Analysis of TNF-α Inhibitors, B Cell Inhibitors, and JAK Inhibitors Versus csDMARDs for Rheumatoid Arthritis Treatment
1个月前
已完结
Long-term outcomes of S-1-based chemoradiotherapy in inoperable elderly patients with esophageal carcinoma: A multicenter, randomized, phase III clinical trial
1个月前
已完结
Atezolizumab plus FOLFOX for Stage III Mismatch Repair–Deficient Colon Cancer
2个月前
已完结
Addition of zoledronic acid to consolidation chemotherapy in Ewing sarcoma—EURO EWING 2012 (EE2012): an international, open-label, randomised controlled phase III trial
3个月前
已完结
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma
4个月前
已完结
Palbociclib for Hormone-Receptor–Positive, HER2-Positive Advanced Breast Cancer
4个月前
已完结
皖公网安备34019202002308
